AU3369200A - Protease inhibitors that overcome drug resistance - Google Patents

Protease inhibitors that overcome drug resistance

Info

Publication number
AU3369200A
AU3369200A AU33692/00A AU3369200A AU3369200A AU 3369200 A AU3369200 A AU 3369200A AU 33692/00 A AU33692/00 A AU 33692/00A AU 3369200 A AU3369200 A AU 3369200A AU 3369200 A AU3369200 A AU 3369200A
Authority
AU
Australia
Prior art keywords
drug resistance
protease inhibitors
overcome drug
overcome
protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU33692/00A
Inventor
Arun K. Ghosh
Jordan J. N. Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
University of Illinois
Original Assignee
Oklahoma Medical Research Foundation
University of Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation, University of Illinois filed Critical Oklahoma Medical Research Foundation
Publication of AU3369200A publication Critical patent/AU3369200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
AU33692/00A 1999-02-19 2000-02-18 Protease inhibitors that overcome drug resistance Abandoned AU3369200A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12083599P 1999-02-19 1999-02-19
US60120835 1999-02-19
PCT/US2000/004215 WO2000048466A2 (en) 1999-02-19 2000-02-18 Protease inhibitors that overcome drug resistance

Publications (1)

Publication Number Publication Date
AU3369200A true AU3369200A (en) 2000-09-04

Family

ID=22392823

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33692/00A Abandoned AU3369200A (en) 1999-02-19 2000-02-18 Protease inhibitors that overcome drug resistance

Country Status (4)

Country Link
EP (1) EP1155009A2 (en)
AU (1) AU3369200A (en)
WO (1) WO2000048466A2 (en)
ZA (1) ZA200107521B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1088098E (en) 1998-06-23 2011-05-25 Univ Illinois Medicament for treating hiv-infected mammals
HN2002000136A (en) 2001-06-11 2003-07-31 Basf Ag INHIBITORS OF THE PROTEASE OF HIV VIRUS, COMPOUNDS CONTAINING THEMSELVES, THEIR PHARMACEUTICAL USES AND THE MATERIALS FOR SYNTHESIS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874745A (en) * 1987-10-01 1989-10-17 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
DE3841732A1 (en) * 1988-12-10 1990-06-13 Hoechst Ag DIPEPTIDE DERIVATIVES WITH ENZYME-INHIBITOR EFFECT
JPH06500561A (en) * 1990-08-24 1994-01-20 ジ・アップジョン・カンパニー Aminopolyol-containing peptides as transition state mimetics
CA2081970C (en) * 1991-11-08 1997-07-08 Joseph P. Vacca Hiv protease inhibitors useful for the treatment of aids

Also Published As

Publication number Publication date
EP1155009A2 (en) 2001-11-21
ZA200107521B (en) 2003-06-25
WO2000048466A3 (en) 2000-12-28
WO2000048466A2 (en) 2000-08-24

Similar Documents

Publication Publication Date Title
AU2001258771A1 (en) -secretase inhibitors
AU5259100A (en) Medicament
AUPQ867700A0 (en) Delivering multimedia descriptions
AU2919001A (en) Syringe
AU6007200A (en) Cysteine protease inhibitors
AU2001274548A1 (en) Syringe
AU2002221099A1 (en) Combination drugs
EP1235577A4 (en) Protease inhibitors
AU3235100A (en) Prothease inhibitors
AU2692200A (en) Enteral sorbefacients
AU1588901A (en) Protease inhibitors
AU2001232244A1 (en) Drug comprising combination
AU2002223313A1 (en) Protease inhibitors and their pharmaceutical uses
AU1474801A (en) Protease inhibitors
EP1231921A4 (en) Protease inhibitors
EP1229915A4 (en) Protease inhibitors
EP1229912A4 (en) Protease inhibitors
AU3888200A (en) Protease inhibitors
AU1474601A (en) Protease inhibitors
AU1474701A (en) Protease inhibitors
AU4066900A (en) Protease inhibitors
EP1229911A4 (en) Protease inhibitors
EP1231923A4 (en) Protease inhibitors
AUPQ180499A0 (en) Beta-amyloid peptide inhibitors
AU3369200A (en) Protease inhibitors that overcome drug resistance

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase